Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Nip The Problem In The Bud - Nay The Leaf
Tobacco is the only consumer product which is grown and available legally and is lethal for human beings. At the current rate, the number of smokers dying every year in the world is likely to reach (10 million) 1 crore by 2020.

New Data From Satraplatin Phase 3 Trial In Second-Line Castrate-Refractory Prostate Cancer Presented At 2009 ASCO Annual Meeting
GPC Biotech AG (FRANKFURT: GPC) (XETRA: GPC) announced that data from the double- blind, randomized satraplatin Phase 3 trial, the SPARC trial (Satraplatin and Prednisone Against Refractory Cancer), were presented at the 2009 American Society for Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida. The SPARC trial evaluated satraplatin plus prednisone versus placebo plus prednisone in 950 patients with castrate-refractory prostate cancer (CRPC) who had progressed after initial chemotherapy. The data presented are retrospective analyses of the SPARC trial evaluating correlations between overall survival (OS) and pain at baseline, pain progression, and progression-free survival (PFS) at three months.
News of the day
More Research Needed To Help Workers With Upper Limb Disorders
A severe lack of evidence is holding doctors back from providing the right treatment for workers suffering from Upper Limb Disorders, according to new research by the NHS Plus funded Occupational Health Clinical Effectiveness Unit (OHCEU) at the Royal College of Physicians. Upper Limb Disorders is an umbrella term for a number of common conditions of the shoulder, arm, wrist and hand, including carpal tunnel syndrome which is estimated to affect around 5% of UK adults
Public Health

Enhancing The Effects Of Platinum-Based Anti-Cancer Drugs

Daqing Li and colleagues, at the University of Pennsylvania School of Medicine, Philadelphia, have identified in vitro and in mice a way to enhance the anticancer effects of the commonly used platinum-based drug cisplatin. For many forms of cancer, including testicular, ovarian, and lung cancer, platinum-based drugs that cause DNA damage are the first choice treatment. However, the utility of these drugs is often limited by the enhanced ability of cancer cells to repair their DNA. As the MRN protein complex, which contains the protein RAD50, has a key role in the molecular pathways that control DNA repair in human cells, Li and colleagues set out to test the hypothesis that attenuating the function of the MRN protein complex might sensitize cancer cells to the effects of cisplatin. The hypothesis was proven using a genetic approach to disrupt MRN function. Specifically, human squamous cell carcinoma cells resistant to the toxic effects of cisplatin became sensitive to the drug when it was combined with an adenoviral vector that drove expression of a dominant-negative RAD50 protein in the cancer cells. Importantly, the combination therapy had potent anti-cancer cell effects in vitro and in mice transplanted with human squamous cell carcinoma cells resistant to cisplatin. The authors therefore hope that it might be possible to develop a clinical strategy to attenuate MRN function and enhance the anticancer effects of platinum-based drugs. TITLE: Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy https://www.the-jci.org/article.php?id=33816 AUTHOR CONTACT: Daqing Li University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA. Karen Honey Journal of Clinical Investigation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009